Corrigendum: Efficacy of Oroxylin A in ameliorating renal fibrosis with emphasis on Sirt1 activation and TGF-β/Smad3 pathway modulation

Front Pharmacol. 2025 Jan 6:15:1548193. doi: 10.3389/fphar.2024.1548193. eCollection 2024.

Abstract

[This corrects the article DOI: 10.3389/fphar.2024.1499012.].

Keywords: Oroxylin A; Sirt1; chronic kidney disease; molecular docking; renal fibrosis.

Publication types

  • Published Erratum